Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annual Review of Pharmacology and Toxicology

• Publication date

  2015-01-06

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1146/annurev-pharmtox-010814-124852PMID 25340933PMCID PMC5051266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood-brain barrier in health and disease.

  2015cited by this paper
• Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.

  2014cited by this paper
• Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

  2014cited by this paper
• Combinatorial approaches for the identification of brain drug delivery targets.

  2014cited by this paper
• Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties.

  2014cited by this paper
• Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion.

  2014cited by this paper
• Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.

  2013cited by this paper
• A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA

  2013influential reference
• Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor

  2013cited by this paper
• Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection.

  2013influential reference
• Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration.

  2013cited by this paper
• Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method.

  2013cited by this paper
• Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.

  2013cited by this paper
• Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.

  2013cited by this paper
• A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo

  2013cited by this paper
• Phase I Study of GRN1005 in Recurrent Malignant Glioma

  2013cited by this paper
• Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s Disease

  2013cited by this paper
• Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

  2013cited by this paper
• Exosomes for targeted siRNA delivery across biological barriers.

  2013cited by this paper
• Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier

  2013influential reference
• Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor

  2013cited by this paper
• Pharmacokinetics and Brain Uptake of an IgG-TNF Decoy Receptor Fusion Protein Following Intravenous, Intraperitoneal and Subcutaneous Administration in the Mouse

  2013cited by this paper
• Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules.

  2013cited by this paper
• The intracellular trafficking pathway of transferrin.

  2012cited by this paper
• Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

  2012cited by this paper
• Glycemic Control and Chronic Dosing of Rhesus Monkeys with a Fusion Protein of Iduronidase and a Monoclonal Antibody Against the Human Insulin Receptor

  2012cited by this paper
• The blood–brain barrier in health and disease

  2012cited by this paper
• Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model

  2012cited by this paper
• ABC transporters in the CNS - an inventory.

  2011cited by this paper
• Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

  2011cited by this paper
• Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

  2011cited by this paper
• CHO cell expression, long‐term stability, and primate pharmacokinetics and brain uptake of an IgG–paroxonase‐1 fusion protein

  2011cited by this paper
• Exosomes as intercellular signalosomes and pharmacological effectors.

  2011cited by this paper
• Brain-Penetrating Tumor Necrosis Factor Decoy Receptor in the Mouse

  2011cited by this paper
• Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor

  2011cited by this paper
• Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG‐iduronate‐2‐sulfatase fusion protein

  2011cited by this paper
• Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.

  2011cited by this paper
• A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo

  2011cited by this paper
• Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors

  2011cited by this paper
• Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer's Disease

  2011cited by this paper
• In Vivo Labeling of Brain Capillary Endothelial Cells after Intravenous Injection of Monoclonal Antibodies Targeting the Transferrin Receptor

  2011cited by this paper
• Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.

  2011cited by this paper
• Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.

  2011cited by this paper
• Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

  2011influential reference
• Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.

  2010influential reference
• IgG‐single chain Fv fusion protein therapeutic for alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey

  2010cited by this paper
• The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells

  2010cited by this paper
• Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer's Disease

  2010cited by this paper
• Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier.

  2010cited by this paper
• Structure and function of the blood-brain barrier.

  2010cited by this paper
• Genetic engineering of IgG-glucuronidase fusion proteins

  2010cited by this paper
• Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse

  2010cited by this paper
• Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.

  2010cited by this paper
• Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.

  2010cited by this paper
• Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.

  2010cited by this paper
• Near Complete Rescue of Experimental Parkinson’s Disease with Intravenous, Non-viral GDNF Gene Therapy

  2009cited by this paper
• AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.

  2009influential reference
• Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer

  2009cited by this paper
• Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse

  2009cited by this paper
• Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.

  2009cited by this paper
• Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.

  2009influential reference
• Comparison of Blood-Brain Barrier Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF Fusion Protein in the Rhesus Monkey

  2009influential reference
• Vesicle Formation and Endocytosis: Function, Machinery, Mechanisms, and Modeling

  2009cited by this paper
• Cellular Elements of the Blood-Brain Barrier

  2009cited by this paper
• The endosomal network.

  2009cited by this paper
• Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones.

  2009cited by this paper
• A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood–Brain Barrier and Provides Neuroprotection

  2009cited by this paper
• Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2

  2008cited by this paper
• Lysosomal Enzyme Replacement of the Brain with Intravenous Non-Viral Gene Transfer

  2008cited by this paper
• GDNF fusion protein for targeted‐drug delivery across the human blood–brain barrier

  2008influential reference
• Identification and Design of Peptides as a New Drug Delivery System for the Brain

  2008cited by this paper
• IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier.

  2008cited by this paper
• Large neutral amino acid transporter enables brain drug delivery via prodrugs.

  2008cited by this paper
• Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.

  2008cited by this paper
• Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2

  2008influential reference
• Physiological pathway for low-density lipoproteins across the blood-brain barrier: transcytosis through brain capillary endothelial cells in vitro.

  2008cited by this paper
• Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier

  2008cited by this paper
• CNS Delivery Via Adsorptive Transcytosis

  2008cited by this paper
• Humanization of anti‐human insulin receptor antibody for drug targeting across the human blood–brain barrier

  2007cited by this paper
• Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation

  2007cited by this paper
• Blood-brain barrier delivery.

  2007cited by this paper
• Gene therapy progress and prospects: Hydrodynamic gene delivery

  2007influential reference
• Design and construction of targeted AAVP vectors for mammalian cell transduction

  2007cited by this paper
• Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development

  2007cited by this paper
• Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.

  2007cited by this paper
• Targeted delivery of proteins across the blood–brain barrier

  2007cited by this paper
• Transvascular delivery of small interfering RNA to the central nervous system

  2007influential reference
• A hybrid vector for ligand-directed tumor targeting and molecular imaging.

  2006cited by this paper
• The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells

  2005cited by this paper
• Organization of vesicular trafficking in epithelia

  2005cited by this paper
• Tissue-Type Plasminogen Activator Crosses the Intact Blood-Brain Barrier by Low-Density Lipoprotein Receptor–Related Protein-Mediated Transcytosis

  2005cited by this paper
• The blood-brain barrier: Bottleneck in brain drug development

  2005cited by this paper
• Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion

  2004cited by this paper
• ABC transporters and the blood-brain barrier.

  2004cited by this paper
• Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier

  2004cited by this paper
• Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake.

  2004cited by this paper
• Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery.

  2003cited by this paper
• A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1

  2003cited by this paper
• High transcytosis of melanotransferrin (P97) across the blood–brain barrier

  2002cited by this paper
• Selection of phage‐displayed llama single‐domain antibodies that transmigrate across human blood‐brain barrier endothelium

  2002cited by this paper

• Aptamer-Based Delivery of Genes and Drugs Across the Blood–Brain Barrier

  2026cites this paper
• Enhanced screening via a pure DNA-encoded peptide library enabled by an Fmoc modification.

  2026cites this paper
• RNA-based approaches for neuroprotection and recovery in ischemic stroke: current evidence and future directions

  2026influential citation
• The Landscape of Ferritin Nanocages for Neurodegenerative Diseases Treatment

  2026cites this paper
• Development of the blood–brain barrier

  2026cites this paper
• Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies

  2025cites this paper
• Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain Barrier.

  2025cites this paper
• Receptor-mediated nose-to-brain delivery of drug combination-loaded polymeric nanocarriers for the treatment of glioblastoma- current progress and future perspectives part I: receptor-mediated nose-to-brain delivery approaches for glioblastoma

  2025cites this paper
• Therapeutic potential of gut microbiota modulation in epilepsy: A focus on short-chain fatty acids.

  2025cites this paper
• Topical delivery of anti-VEGF macromolecules for retinopathy: A review.

  2025cites this paper
• Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of Glioblastoma.

  2025cites this paper
• Nano-biohybrids with cell-penetrating peptides: A molecular trojans for glioblastoma precision medicine.

  2025cites this paper
• Promoting Drug Delivery to the Brain by Modulating the Transcytosis Process across the Blood-Brain Barrier.

  2025cites this paper
• Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies

  2025cites this paper
• Brendo: an open resource for uniquely transcribed genes in brain endothelial cells

  2025cites this paper
• Breaking boundaries: role of the brain barriers in metastatic process

  2025cites this paper
• Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis

  2025cites this paper
• Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system

  2025cites this paper
• Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain

  2025influential citation
• Emerging Strategies for Targeted Drug Delivery across the Blood–Brain Barrier in Neurological Disorder

  2025cites this paper
• Exploring neuropharmacokinetics: mechanisms, models, and clinical implications

  2025cites this paper
• Creation and Improvement of Nanoparticulate Drug Delivery Methods for Penetration of the Blood-Brain Barrier

  2025cites this paper
• Challenges and Opportunities in the Development of Nano-Structured Lipid Carriers for Brain Targeting

  2025cites this paper
• Antioxidant Natural Compounds Integrated with Targeted Protein Degradation: A Multi-Modal Strategy for Alzheimer’s Disease Therapy

  2025cites this paper
• Design and Evaluation of RNA Aptamer–Mediated Delivery of C/EBPβ siRNA for Oncological Therapy

  2025cites this paper
• Molecular and cellular characteristics of cerebrovascular cell types and their contribution to neurodegenerative diseases

  2025cites this paper
• Identifying and Understanding Seizure Liability in Drug Development

  2025cites this paper
• Targeted miRNA Delivery in Epilepsy: Mechanisms, Advances, and Therapeutic Potential

  2025cites this paper
• Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease.

  2025cites this paper
• Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations.

  2025cites this paper
• Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review

  2025cites this paper
• pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma

  2025cites this paper
• Nose‐to‐Brain Delivery of Circular RNA SCMH1‐Loaded Lipid Nanoparticles for Ischemic Stroke Therapy

  2025cites this paper
• Identification of Variable Lymphocyte Receptors That Target the Human Blood–Brain Barrier

  2025cites this paper
• Bacterial infection hypothesis-based therapies for Alzheimer's disease

  2025cites this paper
• Overcoming the Blood–Brain Barrier: Advanced Strategies in Targeted Drug Delivery for Neurodegenerative Diseases

  2025cites this paper
• Promoting transcellular traversal of the blood-brain barrier by simultaneously improving cellular uptake and accelerating lysosomal escape.

  2025cites this paper
• Lactoferrin Nanoparticle-Vanadium Complex: A Promising High-Efficiency Agent against Glioblastoma by Triggering Autophagy and Ferroptosis.

  2025cites this paper
• Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood–Brain Barrier and Blood–Tumor Barrier

  2025cites this paper
• Affinity-based drug delivery systems for the central nervous system: exploiting molecular interactions for local, precise targeting

  2024cites this paper
• Engineered brain‐targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma

  2024cites this paper
• Systemic Brain Delivery of Oligonucleotide Therapeutics Enhanced by Protein Corona‐Assisted DNA Cubes

  2024cites this paper
• Exosomes as a therapeutic tool to promote neurorestoration and cognitive function in neurological conditions: Achieve two ends with a single effort

  2024cites this paper
• Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood–Brain Barrier Crossing Ability

  2024cites this paper
• Improving drug delivery to the brain: the prodrug approach

  2024cites this paper
• Characterizing emerging companies in computational drug development

  2024influential citation
• Drug Design for Alzheimer's Disease: Biologics vs. Small Molecules.

  2024cites this paper
• Engineered exosomes with enhanced stability and delivery efficiency for glioblastoma therapy.

  2024cites this paper
• The anterior chamber of the eye technology and its anatomical, optical, and immunological bases

  2024cites this paper
• A Human Brain-Chip for modelling brain pathologies and screening of BBB crossing therapeutic strategies

  2024cites this paper
• Silica Nanoparticle Exposure Implicates β-Amyloid (1-42) Inbound and the Accelerating Alzheimer's Disease Progression in Mice Overexpressing Mutated Forms of Human Amyloid Precursor Protein and Presenilin 1 Genes.

  2024cites this paper
• The solute carrier SLC7A1 may act as a protein transporter at the blood-brain barrier.

  2024cites this paper
• Targeted gene delivery through receptors with lipid nanoparticles

  2024cites this paper
• Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer’s disease progression

  2024cites this paper
• The Tumor-Derived Exosomes Enhanced Bevacizumab across the Blood-Brain Barrier for Antiangiogenesis Therapy against Glioblastoma.

  2024cites this paper
• Construction of Nicotinamide Mononucleotide-Loaded Liposomes and Their In Vitro Transport Across the Blood–Brain Barrier

  2024cites this paper
• Unlocking Therapeutic Potential of siRNA-based Drug Delivery System for Treatment of Alzheimer's Disease

  2024cites this paper
• Bio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy

  2024cites this paper
• Ex vivo nanoscale abluminal mapping of putative cargo receptors at the blood-brain barrier of expanded brain capillaries

  2024cites this paper
• The Potential of Nano Pharmaceuticals to Change the Paradigm of Brain Tumor Therapy: A State-of-the-Art Review.

  2024cites this paper
• Brain-targeting redox-sensitive micelles for codelivery of TMZ and β-lapachone for glioblastoma therapy.

  2024cites this paper
• Emerging trends in virus and virus-like particle gene therapy delivery to the brain

  2024cites this paper
• Rational design of siRNA-based delivery systems for effective treatment of brain diseases

  2024cites this paper
• Amyloid-β-targeting immunotherapies for Alzheimer's disease.

  2024cites this paper
• Research Progress on the Strategies for Crossing the Blood-Brain Barrier.

  2024cites this paper
• Systematic Reversal of Drug Resistance in Cancer

  2024cites this paper
• Wnt-Regulated Therapeutics for Blood-Brain Barrier Modulation and Cancer Therapy.

  2024cites this paper
• Nanoparticle targeting strategies for traumatic brain injury

  2024cites this paper
• A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies

  2024cites this paper
• Detection of molecular markers of ferroptosis in human Alzheimer's disease brains

  2024cites this paper
• Small volume blood-brain barrier opening in macaques with a 1 MHz ultrasound phased array

  2023cites this paper
• Molecular Identity Changes of Tumor-Associated Macrophages and Microglia After Magnetic Resonance Imaging-Guided Focused Ultrasound-Induced Blood-Brain Barrier Opening in a Mouse Glioblastoma Model.

  2023cites this paper
• Modelling a Human Blood-Brain Barrier Co-Culture Using an Ultrathin Silicon Nitride Membrane-Based Microfluidic Device

  2023cites this paper
• Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme

  2023cites this paper
• Recent progress in nanomedicines for imaging and therapy of brain tumors.

  2023cites this paper
• Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery.

  2023cites this paper
• Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers

  2023cites this paper
• Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer's disease.

  2023cites this paper
• Subcellular trafficking and transcytosis efficacy of different receptor types for therapeutic antibody delivery at the blood‒brain barrier

  2023cites this paper
• Recent Advancements and Strategies for Overcoming the Blood–Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma

  2023influential citation
• Recent Advances in Delivery of Peptide and Protein Therapeutics to the Brain

  2023influential citation
• Receptor–mediated transcytosis of macromolecules across the blood–brain barrier

  2023cites this paper
• Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease.

  2023cites this paper
• Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

  2023cites this paper
• Transferrin functionalized poloxamer-chitosan nanoparticles of metformin: physicochemical characterization, in-vitro, and Ex-vivo studies

  2023cites this paper
• Recent advances in nanotechnology for combating Alzheimer's disease

  2023cites this paper
• In-Situ Gels for Brain Delivery: Breaching the Barriers.

  2023cites this paper
• Influence factors on and potential strategies to amplify receptor-mediated nanodrug delivery across the blood–brain barrier

  2023influential citation
• Theoretical design for covering Engeletin with functionalized nanostructure-lipid carriers as neuroprotective agents against Huntington’s disease via the nasal-brain route

  2023cites this paper
• An Overview of Current Progress and Challenges in Brain Cancer Therapy Using Advanced Nanoparticles.

  2023cites this paper
• A dual-targeting peptide for glioblastoma screened by phage display peptide library biopanning combined with affinity-adaptability analysis.

  2023cites this paper
• Pathogenic bacteria exploit transferrin receptor transcytosis to penetrate the blood–brain barrier

  2023cites this paper
• Applications of Nanoparticles in Alzheimer’s Disease

  2023cites this paper
• Small volume blood-brain barrier opening in macaques with a 1 MHz ultrasound phased array.

  2023cites this paper
• A blood-brain barrier crossing peptide

  2023cites this paper
• Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment.

  2023cites this paper
• Recent Advancements in Nanocarrier-assisted Brain Delivery of Phytochemicals Against Neurological Diseases

  2023cites this paper
• Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier

  2023cites this paper
• CmPn/CmP Signaling Networks in the Maintenance of the Blood Vessel Barrier

  2023cites this paper
• Molecular Trojan Horses for treating lysosomal storage diseases.

  2023cites this paper